• Board action on Oct. 29, 2025 set up an offering of Class A Multiple Voting Shares to restore voting control toward IPO levels.
• If fully subscribed, Class A voting rights rise to 75.27% from 46.52% following years of Class B Subordinate Voting Share issuances.
• Directors held informal discussions excluding Zeeshan Saeed and Anthony Durkacz; both abstained due to conflicts under the OBCA.
• Proceeds earmarked for general working capital; new Class A shares carry a four-month-and-one-day Canadian hold period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quantum Biopharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001185185-26-004098), on September 17, 2026, and is solely responsible for the information contained therein.